Get access

Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency


Wing-Yen Wong, Childrens Hospital Los Angeles, Department of Hematology-Oncology, 4650 Sunset Blvd M/S 54, Los Angeles, CA 90027, USA.
Tel.: 323/669-4628; fax: 323/660-7128;


Summary.  Use of recombinant factor VIIa (rFVIIa, NovoSeven®) in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half-life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII-deficient adolescent.